UNLIMITED TURBO LONG - ASTRAZENECA | Delayed Börse Stuttgart 03:44:42 2024-06-03 am EDT | ||
| 0.64 EUR | +10.34% |
|
| 1 month | -15.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 0.64 | +10.34% |
| 24-05-31 | 0.58 | +3.57% |
| 24-05-30 | 0.56 | -5.08% |
| 24-05-29 | 0.59 | -24.36% |
| 24-05-28 | 0.78 | -17.02% |
Delayed Quote Börse Stuttgart
Last update June 03, 2024 at 03:44 am EDT
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| WKN | PC8ZLY |
| ISIN | DE000PC8ZLY5 |
| Date issued | 2024-04-26 |
| Strike | 11,611 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.56 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.06 € |
|---|---|
| Lowest since issue | 0.56 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.91%
- Stock Market
- Certificates
- Certificat
